Nuclear breast imaging: Clinical results and future directions

Journal of Nuclear Medicine

Volumn 57, Issue , 2016, Pages 46S-52S

  Berg, Wendie A ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Breast cancer; Breast MRI; Breast PET; Molecular breast imaging; Positron emission mammography; Screening

Indexed keywords

FLUORODEOXYGLUCOSE F 18; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M;

ARTICLE; BREAST CANCER; BREAST DENSITY; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER SCREENING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC IMAGING; DISEASE SEVERITY; HIGH RISK POPULATION; HUMAN; INTERMETHOD COMPARISON; IONIZING RADIATION; MAMMOGRAPHY; NUCLEAR BREAST IMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PREDICTIVE VALUE; PRIORITY JOURNAL; RADIATION DOSE; RADIATION EXPOSURE; RECURRENCE RISK; SENSITIVITY AND SPECIFICITY; BREAST; BREAST TUMOR; FEMALE; MOLECULAR IMAGING; POSITRON EMISSION TOMOGRAPHY; SCINTISCANNING;

BREAST; BREAST NEOPLASMS; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MAMMOGRAPHY; MOLECULAR IMAGING; POSITRON-EMISSION TOMOGRAPHY;

EID: 84958749556     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.115.157891     Document Type: Article

References (79)

1. Baldwin JA, Bag AK, White SL, Palot-Manzil FF, OMalley JP. All you need to know as an authorized user. AJR. 2015;205:251-258
2. Khalkhali I, Villanueva-Meyer J, Edell SL, et al. Diagnostic accuracy of 99mTcsestamibi breast imaging: multicenter trial results. J Nucl Med. 2000;41:1973-1979
3. Avril N, Rose CA, Schelling M, et al. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol. 2000;18:3495-3502
4. Tadwalkar RV, Rapelyea JA, Torrente J, et al. Breast-specific gamma imaging as an adjunct modality for the diagnosis of invasive breast cancer with correlation to tumour size and grade. Br J Radiol. 2012;85:e212-e216
5. Hruska CB, Boughey JC, Phillips SW, et al. Scientific Impact Recognition Award: molecular breast imaging - A review of the Mayo Clinic experience. Am J Surg. 2008;196:470-476
6. Conners AL, Jones KN, Hruska CB, Geske JR, Boughey JC, Rhodes DJ. Directconversion molecular breast imaging of invasive breast cancer: Imaging features, extent of invasive disease, and comparison between invasive ductal and lobular histology. AJR. 2015;205:W374-W381
7. Hruska CB, Rhodes DJ, Collins DA, Tortorelli CL, Askew JW, OConnor MK. Evaluation of molecular breast imaging in women undergoing myocardial perfusion imaging with 99mTc-sestamibi. J Womens Health (Larchmt). 2012;21:730-738
8. Kalinyak JE, Berg WA, Schilling K, Madsen KS, Narayanan D, Tartar M. Breast cancer detection using high-resolution breast PET compared to whole-body PET or PET/CT. Eur J Nucl Med Mol Imaging. 2014;41:260-275
9. Eo JS, Chun IK, Paeng JC, et al. Imaging sensitivity of dedicated positron emission mammography in relation to tumor size. Breast. 2012;21:66-71
10. Berg WA, Madsen KS, Schilling K, et al. Breast cancerComparative effectiveness of positron emission mammography and MR imaging in presurgical planning for the ipsilateral breast. Radiology. 2011;258:59-72
11. OConnor MK, Hruska CB, Tran TD, et al. Factors influencing the uptake of 99mTc-sestamibi in breast tissue on molecular breast imaging. J Nucl Med Technol. 2015;43:13-20
12. Hruska CB, Weinmann AL, Tello Skjerseth CM, et al. Proof of concept for lowdose molecular breast imaging with a dual-head CZT gamma camera: part II-evaluation in patients. Med Phys. 2012;39:3476-3483
13. Mettler FAJ, Huda W, Yoshizumi TT, Mahesh M. Effective doses in radiology and diagnostic nuclear medicine: A catalog. Radiology. 2008;248:254-263
14. Swanson TN, Troung DT, Paulsen A, Hruska CB, OConnor MK. Adsorption of 99mTc-sestamibi onto plastic syringesEvaluation of factors affecting the degree of adsorption and their impact on clinical studies. J Nucl Med Technol. 2013;41: 247-252
15. Hendrick RE. Radiation doses and cancer risks from breast imaging studies. Radiology. 2010;257:246-253
16. AAPM position statement on radiation risks from medical imaging procedures. American Association of Physicists in Medicine website. http://www.aapm.org/ org/policies/details.asp?id5318&type5PP¤t5true. Published December 13, 2011. Accessed November 17, 2015.
17. Weigert JM, Bertrand ML, Lanzkowsky L, Stern LH, Kieper DA. Results of a multicenter patient registry to determine the clinical impact of breast-specific gamma imaging: A molecular breast imaging technique. AJR. 2012;198:W69-W75
18. Brem RF, Floerke AC, Rapelyea JA, Teal C, Kelly T, Mathur V. Breast-specific gamma imaging as an adjunct imaging modality for the diagnosis of breast cancer. Radiology. 2008;247:651-657
19. Wahner-Roedler DL, Hruska CB, OConnor MK, et al. Molecular breast imaging for women presenting with a history of nonreproducible bloody nipple discharge and negative findings on routine imaging studies: A pilot study. J Surg Radiol. 2011;2:92-99
20. Houssami N, Ciatto S, Macaskill P, et al. Accuracy and surgical impact of magnetic resonance imaging in breast cancer staging: systematic review and meta-analysis in detection of multifocal and multicentric cancer. J Clin Oncol. 2008;26:3248-3258
21. Brennan ME, Houssami N, Lord S, et al. Magnetic resonance imaging screening of the contralateral breast in women with newly diagnosed breast cancer: systematic review and meta-analysis of incremental cancer detection and impact on surgical management. J Clin Oncol. 2009;27:5640-5649
22. Brem RF, Shahan C, Rapelyea JA, et al. Detection of occult foci of breast cancer using breast-specific gamma imaging in women with one mammographic or clinically suspicious breast lesion. Acad Radiol. 2010;17:735-743
23. Zhou M, Johnson N, Gruner S, et al. Clinical utility of breast-specific gamma imaging for evaluating disease extent in the newly diagnosed breast cancer patient. Am J Surg. 2009;197:159-163
24. Killelea BK, Gillego A, Kirstein LJ, et al. George Peters Award: how does breast-specific gamma imaging affect the management of patients with newly diagnosed breast cancer? Am J Surg. 2009;198:470-474
25. Kim BS. Usefulness of breast-specific gamma imaging as an adjunct modality in breast cancer patients with dense breast: A comparative study with MRI. Ann Nucl Med. 2012;26:131-137
26. Edwards C, Williams S, McSwain AP, et al. Breast-specific gamma imaging influences surgical management in patients with breast cancer. Breast J. 2013;19:512-519
27. Berg WA, Madsen KS, Schilling K, et al. Comparative effectiveness of positron emission mammography and MRI in the contralateral breast of women with newly diagnosed breast cancer. AJR. 2012;198:219-232
28. Houssami N, Turner R, Macaskill P, et al. An individual person data metaanalysis of preoperative magnetic resonance imaging and breast cancer recurrence. J Clin Oncol. 2014;32:392-401
29. Bae MS, Moon HG, Han W, et al. Early stage triple-negative breast cancer: Imaging and clinical-pathologic factors associated with recurrence. Radiology. July 31, 2015 [Epub ahead of print].
30. Solin LJ, Orel SG, Hwang WT, Harris EE, Schnall MD. Relationship of breast magnetic resonance imaging to outcome after breast-conservation treatment with radiation for women with early-stage invasive breast carcinoma or ductal carcinoma in situ. J Clin Oncol. 2008;26:386-391
31. Turnbull L, Brown S, Harvey I, et al. Comparative effectiveness of MRI in breast cancer (COMICE) trial: A randomised controlled trial. Lancet. 2010;375:563-571
32. Peters NH, van Esser S, van den Bosch MA, et al. Preoperative MRI and surgical management in patients with nonpalpable breast cancer: the MONET-randomised controlled trial. Eur J Cancer. 2011;47:879-886
33. Mann RM, Loo CE, Wobbes T, et al. The impact of preoperative breast MRI on the re-excision rate in invasive lobular carcinoma of the breast. Breast Cancer Res Treat. 2010;119:415-422
34. Rodenko GN, Harms SE, Pruneda JM, et al. MR imaging in the management before surgery of lobular carcinoma of the breastCorrelation with pathology. AJR. 1996;167:1415-1419
35. Werner J, Rapelyea JA, Yost KG, Brem RF. Quantification of radio-tracer uptake in axillary lymph nodes using breast specific gamma imaging (BSGI): Benign radio-tracer extravasation versus uptake secondary to breast cancer. Breast J. 2009;15:579-582
36. Pan L, Han Y, Sun X, Liu J, Gang H. FDG-PET and other imaging modalities for the evaluation of breast cancer recurrence and metastases: A meta-analysis. J Cancer Res Clin Oncol. 2010;136:1007-1022
37. Nelson HD, Tyne K, Naik A, Bougatsos C, Chan BK, Humphrey L. Screening for breast cancer: An update for the U.S. Preventive Services Task Force. Ann Intern Med. 2009;151:727-737, W237-W242
38. Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. 2007;57:75-89
39. Harvey JA, Bovbjerg VE. Quantitative assessment of mammographic breast density: Relationship with breast cancer risk. Radiology. 2004;230:29-41
40. Kerlikowske K, Zhu W, Hubbard RA, et al. Outcomes of screening mammography by frequency, breast density, and postmenopausal hormone therapy. JAMA Intern Med. 2013;173:807-816
41. Rechtman LR, Lenihan MJ, Lieberman JH, et al. Breast-specific gamma imaging for the detection of breast cancer in dense versus nondense breasts. AJR. 2014; 202:293-298
42. Legislation and regulations: what is required? DenseBreast-info website. http:// densebreast-info.org/legisiation.aspx. Revised September 15, 2015. Accessed November 17, 2015.
43. Sickles EA, DOrsi CJ, Bassett LW, et al. ACR BI-RADS mammography. In: ACR BI-RADS Atlas, Breast Imaging Reporting and Data System. Reston, VA: American College of Radiology; 2013.
44. Brem RF, Rapelyea JA, Zisman G, et al. Occult breast cancer: scintimammography with high-resolution breast-specific gamma camera in women at high risk for breast cancer. Radiology. 2005;237:274-280
45. Rhodes DJ, Hruska CB, Conners AL, et al. Journal club: molecular breast imaging at reduced radiation dose for supplemental screening in mammographically dense breasts. AJR. 2015;204:241-251
46. Rhodes DJ, Hruska CB, Phillips SW, Whaley DH, OConnor MK. Dedicated dual-head gamma imaging for breast cancer screening in women with mammographically dense breasts. Radiology. 2011;258:106-118
47. Hruska CB, Conners AL, Jones KN, et al. Diagnostic workup and costs of a single supplemental molecular breast imaging screen of mammographically dense breasts. AJR. 2015;204:1345-1353
48. Kalinyak JE, Schilling K, Berg WA, et al. PET-guided breast biopsy. Breast J. 2011;17:143-151
49. Conners AL, Maxwell RW, Tortorelli CL, et al. Gamma camera breast imaging lexicon. AJR. 2012;199:W767-W774
50. Narayanan D, Madsen KS, Kalinyak JE, Berg WA. Interpretation of positron emission mammography: feature analysis and rates of malignancy. AJR. 2011;196:956-970
51. Conners AL, Hruska CB, Tortorelli CL, et al. Lexicon for standardized interpretation of gamma camera molecular breast imaging: observer agreement and diagnostic accuracy. Eur J Nucl Med Mol Imaging. 2012;39:971-982
52. Narayanan D, Madsen KS, Kalinyak JE, Berg WA. Interpretation of positron emission mammography and MRI by experienced breast imaging radiologists: performance and observer reproducibility. AJR. 2011;196:971-981
53. Mendelson EB, Bhm-Vlez M, Berg WA, et al. ACR BI-RADS ultrasound. In: ACR BI-RADS Atlas, Breast Imaging Reporting and Data System. Reston, VA: American College of Radiology; 2013.
54. Morris EA, Comstock CE, Lee C, et al. ACR BI-RADS magnetic resonance imaging. In: ACR BI-RADS Atlas, Breast Imaging Reporting and Data System. Reston, VA: American College of Radiology; 2013.
55. Sickles EA, DOrsi CJ. Follow-up and outcome monitoring. In: ACR BI-RADS Atlas, Breast Imaging Reporting and Data System. Reston, VA: American College of Radiology; 2013.
56. Hruska CB, OConnor MK. Quantification of lesion size, depth, and uptake using a dual-head molecular breast imaging system. Med Phys. 2008;35:1365-1376
57. Hruska CB, Conners AL, Vachon CM, et al. Effect of menstrual cycle phase on background parenchymal uptake at molecular breast imaging. Acad Radiol. 2015; 22:1147-1156
58. Hruska CB, Rhodes DJ, Conners AL, et al. Background parenchymal uptake during molecular breast imaging and associated clinical factors. AJR. 2015;204: W363-W370
59. King V, Brooks JD, Bernstein JL, Reiner AS, Pike MC, Morris EA. Background parenchymal enhancement at breast MR imaging and breast cancer risk. Radiology. 2011;260:50-60
60. Dontchos BN, Rahbar H, Partridge SC, et al. Are qualitative assessments of background parenchymal enhancement, amount of fibroglandular tissue on MR images, and mammographic density associated with breast cancer risk? Radiology. 2015;276:371-380
61. Berg WA, Weinberg IN, Narayanan D, et al. High-resolution fluorodeoxyglucose positron emission tomography with compression (positron emission mammography) is highly accurate in depicting primary breast cancer. Breast J. 2006;12:309-323
62. Mendelson EB, Harris KM, Doshi N, Tobon H. Infiltrating lobular carcinoma: mammographic patterns with pathologic correlation. AJR. 1989;153:265-271
63. Brem RF, Ioffe M, Rapelyea JA, et al. Invasive lobular carcinomaDetection with mammography, sonography, MRI, and breast-specific gamma imaging. AJR. 2009; 192:379-383
64. Brem RF, Fishman M, Rapelyea JA. Detection of ductal carcinoma in situ with mammography, breast specific gamma imaging, and magnetic resonance imaging: A comparative study. Acad Radiol. 2007;14:945-950
65. Kim BS, Sung SH. Usefulness of 18F-FDG uptake with clinicopathologic and immunohistochemical prognostic factors in breast cancer. Ann Nucl Med. 2012;26:175-183
66. Groheux D, Giacchetti S, Moretti JL, et al. Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging. 2011;38:426-435
67. Garcia Vicente AM, Soriano Castrejon A, Leon Martin A, et al. Molecular subtypes of breast cancer: metabolic correlation with 18F-FDG PET/CT. Eur J Nucl Med Mol Imaging. 2013;40:1304-1311
68. Oshida M, Uno K, Suzuki M, et al. Predicting the prognoses of breast carcinoma patients with positron emission tomography using 2-deoxy-2-fluoro-18F-D-glucose. Cancer. 1998;82:2227-2234
69. Mitchell D, Hruska CB, Boughey JC, et al. 99mTc-sestamibi using a direct conversion molecular breast imaging system to assess tumor response to neoadjuvant chemotherapy in women with locally advanced breast cancer. Clin Nucl Med. 2013;38:949-956
70. Groheux D, Hindie E, Giacchetti S, et al. Triple-negative breast cancerEarly assessment with 18F-FDG PET/CT during neoadjuvant chemotherapy identifies patients who are unlikely to achieve a pathologic complete response and are at a high risk of early relapse. J Nucl Med. 2012;53:249-254
71. Schillaci O, Spanu A, Danieli R, Madeddu G. Molecular breast imaging with gamma emitters. Q J Nucl Med Mol Imaging. 2013;57:340-351
72. Spanu A, Sanna D, Chessa F, Cottu P,Manca A,Madeddu G. Breast scintigraphy with breast-specific g-camera in the detection of ductal carcinoma in situ: A correlation with mammography and histologic subtype. J Nucl Med. 2012;53:1528-1533
73. Bach-Gansmo T, Bogsrud TV, Skretting A. Integrin scintimammography using a dedicated breast imaging, solid-state g-camera and 99mTc-labelled NC100692. Clin Physiol Funct Imaging. 2008;28:235-239
74. van Kruchten M, Glaudemans AW, de Vries EF, et al. PET imaging of estrogen receptors as a diagnostic tool for breast cancer patients presenting with a clinical dilemma. J Nucl Med. 2012;53:182-190
75. Linden HM, Stekhova SA, Link JM, et al. Quantitative fluoroestradiol positron emission tomography imaging predicts response to endocrine treatment in breast cancer. J Clin Oncol. 2006;24:2793-2799
76. Kong FL, Kim EE, Yang DJ. Targeted nuclear imaging of breast cancer: status of radiotracer development and clinical applications. Cancer Biother Radiopharm. 2012;27:105-112
77. Jochelson MS, Dershaw DD, Sung JS, et al. Bilateral contrast-enhanced dualenergy digital mammography: feasibility and comparison with conventional digital mammography and MR imaging in women with known breast carcinoma. Radiology. 2013;266:743-751
78. Lewin JM, Isaacs PK, Vance V, Larke FJ. Dual-energy contrast-enhanced digital subtraction mammography: feasibility. Radiology. 2003;229:261-268
79. Ling CM, Coffey CM, Rapelyea JA, et al. Breast-specific gamma imaging in the detection of atypical ductal hyperplasia and lobular neoplasia. Acad Radiol. 2012; 19:661-666